Dashboard
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate -7.93% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -118.62
2
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
SEK 2,744 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-1.20
103.65%
-4.89
Revenue and Profits:
Net Sales:
49 Million
(Quarterly Results - Jun 2025)
Net Profit:
-179 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-79.33%
0%
-79.33%
6 Months
-79.33%
0%
-79.33%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Hansa Biopharma AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
119.95%
EBIT Growth (5y)
-7.93%
EBIT to Interest (avg)
-118.62
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.22
Sales to Capital Employed (avg)
0.30
Tax Ratio
0.49%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-8.23
EV to EBIT
-7.79
EV to EBITDA
-7.79
EV to Capital Employed
38.79
EV to Sales
21.26
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-498.16%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
49.10
66.30
-25.94%
Operating Profit (PBDIT) excl Other Income
-155.50
-94.40
-64.72%
Interest
13.30
29.50
-54.92%
Exceptional Items
-59.40
0.00
Consolidate Net Profit
-178.90
-37.10
-382.21%
Operating Profit Margin (Excl OI)
-3,165.60%
-1,423.30%
-174.23%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -25.94% vs 105.26% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -382.21% vs 86.58% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
171.30
134.10
27.74%
Operating Profit (PBDIT) excl Other Income
-591.40
-780.10
24.19%
Interest
121.40
105.50
15.07%
Exceptional Items
-12.80
0.00
Consolidate Net Profit
-807.20
-831.70
2.95%
Operating Profit Margin (Excl OI)
-3,615.70%
-5,897.90%
228.22%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 27.74% vs -13.20% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 2.95% vs -36.10% in Dec 2023
About Hansa Biopharma AB 
Hansa Biopharma AB
Pharmaceuticals & Biotechnology
Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.
Company Coordinates 
Company Details
Scheelevagen 22,, P.O. Box 785 LUND None : 220 07
Registrar Details






